Analyzing the structure of existing biomarkers could reveal new information about cancer, helping laboratories deliver more accurate and clinically useful results.
An independent validation study of 426 patients evaluated the assay's ability to assess 10-year recurrence risk and identify patients more likely to benefit from radiation therapy.
The FDA has cleared Aptitude’s next-generation Metrix COVID Test, which the company says offers 3-fold higher sensitivity and 30% faster results compared to its EUA version.
Cerenome has launched two CSF-based molecular profiling tests for CNS cancers, offering DNA and RNA sequencing panels to evaluate primary, metastatic, and hematologic malignancies in the central nervous system.
A peer-reviewed study reports ACES Diagnostics’ LymeSeek immunoassay achieved 90% sensitivity for early Lyme disease detection within two weeks of symptom onset.
General practitioner requests for AMH fertility tests rose more than 13-fold from 2011 to 2021, despite research showing these tests cannot predict natural conception, according to a Flinders University study of 1.4 million health records.
Werfen has launched a web-based platform designed to centralize autoimmune testing data, automate workflows, and integrate with laboratory information systems for high-volume clinical labs.
A peer-reviewed study found that Olink proximity extension assay technology correlates with ELISA for measuring endothelin-1 in coronary artery plasma, supporting its use for high-throughput proteomics in clinical research.
Lund University has received a $19.4 million NIH grant to clinically validate a new blood biomarker test for Alzheimer’s, assessing MTBR-tau243 and p-tau217 for improved disease staging and diagnostic accuracy.
Revvity has introduced the CE-IVDR-certified GSP T1D 3plex kit, a multiplex dried blood spot assay for early type 1 diabetes screening in children, designed to support population-level programs.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Tampa General Hospital is the first in the Southeast to implement the MeMed BV host-response test in its emergency workflow, reporting a 33% reduction in cefepime use and 13% fewer hospitalizations, according to hospital-led research.